Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients

Publisher Website
Google Scholar
Abstract
Høgdall CK, Høgdall EVS, Hørding U, Clemmensen I, N0rgaard-Pedersen B, Toftager-Larsen K. Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest 1993; 53: 741-746. Plasma tetranectin (TN) was tested as a biochemical prognostic marker in ovarian cancer on 39 patients. In stage I + II the 5-year survival was 33% (2/6) if plasma TN was ≤ 6.7mgl−1 and 100% (15/15) with plasma TN > 6.7 mgl−1. For stage III + IV the survival was 0% (0/11) at 26 months for patients with plasma TN ≤ 6.7 mgl−1 and 29% (2/7) after 5 years with plasma TN > 6.7mgl−1. By multivariate testing the relative hazard (RH) of death was found to be 73 times higher in patients with plasma TN ≤ 6.7mgl−1 compared to patients with values above 6.7mgl_1 (p < 0.001). For comparison, the maximal RH for the other tested variables were: 15 for advanced stage, 2.5 for grade, four for residual tumour and 2.5 for younger age.